Ronan Talty, MD, PhD
About
Biography
Dr. Talty is an MD/PhD student at Yale School of Medicine. Prior to medical school, he graduated summa cum laude from Northeastern University with a degree in behavioral neuroscience. There, he completed research projects on pathological neural network activation in seizures, the impact of charged particle radiation on cognitive function, and the ability of estrogen to modulate dopamine action in the brain and affect memory for traumatic events, and received multiple conference awards, research fellowships, and university honors.
During medical school, Dr. Talty developed a passion for cancer biology and earned his PhD studying melanoma under the mentorship of Dr. Marcus Bosenberg. His thesis research focused on ferroptosis, a novel form of regulated cell death. He investigated the role of ferroptosis in endogenous and immunotherapy-induced antitumor immunity, pharmacologic strategies to enhance intratumoral ferroptosis and immunotherapy responses, and the impact of mutations in oncogenes such as BRAF, NRAS, and KRAS on ferroptosis sensitivity. He has delivered oral presentations on his work to international audiences at the Society for Melanoma Research and American Association for Cancer Research annual meetings. His research is supported by an NRSA F30 predoctoral fellowship from the National Cancer Institute and a medical student grant from the American Skin Association
Dr. Talty maintains a broad interest in tumor immunology and metabolism. His clinical interests include dermatology, inflammatory skin disorders, and melanoma and other skin cancers. Starting this July, he will complete his intern year at Memorial Sloan Kettering Cancer Center before his dermatology residency at New York University Grossman School of Medicine.
Education & Training
- MD
- Yale School of Medicine (2024)
- PhD
- Yale School of Medicine, Experimental Pathology (2023)
- BS
- Northeastern University, Behavioral Neuroscience (2017)
Research
Research at a Glance
Yale Co-Authors
Publications Timeline
Caroline Helen Johnson, PhD
Goran Micevic, MD, PhD
Marcus Bosenberg, MD, PhD
Akiko Iwasaki, PhD
Andrew Daniels, PhD
Esen Sefik
Publications
2023
IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory
Micevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn H, Sefik E, Cheung J, Hornick N, Aizenbud L, Joshi N, Kluger H, Iwasaki A, Bosenberg M, Flavell R. IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2304319120. PMID: 37459511, PMCID: PMC10372654, DOI: 10.1073/pnas.2304319120.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIL-7R expressionT cellsIL-7RAntitumor memorySuperior antitumor efficacyCell-based therapiesTumor-specific T cellsAntigen-specific T cellsAntitumor efficacyPowerful antitumor immune responseMarkers of exhaustionTumor-specific CD8Antitumor immune responseIndependent prognostic factorAntitumor immune memoryMemory T cellsMajor risk factorSuperior antitumor activityFunctional CD8Memory CD8Prognostic factorsSurgical resectionAdvanced melanomaLymph nodesNaive miceDiscovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations
Yan H, Talty R, Jain A, Cai Y, Zheng J, Shen X, Muca E, Paty P, Bosenberg M, Khan S, Johnson C. Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations. Redox Biology 2023, 62: 102699. PMID: 37086630, PMCID: PMC10172914, DOI: 10.1016/j.redox.2023.102699.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsKRAS mutant tumorsMale CRC patientsCRC patientsMale patientsKRAS mutationsMutant tumorsOverall survivalMale colorectal cancer patientsKRAS wild-type tumorsAberrant tumor metabolismColorectal cancer patientsCRC patient cohortsColorectal cancer casesFerroptosis-related genesWild-type tumorsNovel potential avenuesNormal colon tissuesPoor OSKRAS statusAdverse outcomesCRC cellsPatient cohortCancer patientsType tumorsCancer casesFerroptosis in colorectal cancer: a future target?
Yan H, Talty R, Aladelokun O, Bosenberg M, Johnson C. Ferroptosis in colorectal cancer: a future target? British Journal Of Cancer 2023, 128: 1439-1451. PMID: 36703079, PMCID: PMC10070248, DOI: 10.1038/s41416-023-02149-6.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsColorectal cancerRegulated cell deathCurrent treatment optionsForms of RCDCancer deathTreatment optionsCRC therapyCancer recurrenceTreatment strategiesRadiation therapyOvert toxicityTherapeutic targetDrug resistanceTherapyCancer cellsFerroptosisPotential roleCancerCell deathFuture targetsDeathRecent studiesBiological pathwaysChemotherapySurgery
2022
Targeting ferroptosis to treat colorectal cancer
Yan H, Talty R, Johnson C. Targeting ferroptosis to treat colorectal cancer. Trends In Cell Biology 2022, 33: 185-188. PMID: 36473802, DOI: 10.1016/j.tcb.2022.11.003.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsProtein kinase BArachidonic acidColorectal cancer treatmentProtein kinaseKinase BMammalian targetKey pathwaysGlutathione metabolismFerroptosis inductionEnergy metabolismCRC treatmentColorectal cancerCRC pathogenesisFerroptosisCancer treatmentPromising targetNew conceptual avenuesMetabolismTreatmentHippoKinasePrimary strategyRapamycinTargetConceptual avenuesErythrodermic scabies in an immunocompetent patient
Talty R, Micevic G, Damsky W, King BA. Erythrodermic scabies in an immunocompetent patient. JAAD Case Reports 2022, 29: 112-115. PMID: 36262356, PMCID: PMC9573821, DOI: 10.1016/j.jdcr.2022.08.045.Peer-Reviewed Original ResearchCitationsAltmetricSisaipho alopecia areata treated with tofacitinib and oral minoxidil
Talty R, Damsky W, King B. Sisaipho alopecia areata treated with tofacitinib and oral minoxidil. JAAD Case Reports 2022, 29: 41-42. PMID: 36193241, PMCID: PMC9525808, DOI: 10.1016/j.jdcr.2022.08.037.Peer-Reviewed Original ResearchCitationsLeukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Talty R, Micevic G, Wang A, Ko CJ, Damsky W. Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist. Case Reports In Dermatology 2022, 14: 214-218. PMID: 36158852, PMCID: PMC9459519, DOI: 10.1159/000525894.Peer-Reviewed Original ResearchConceptsRestless legs syndromeRotigotine patchTransdermal patchRotigotine transdermal patchTransdermal dopamine agonistsPotential side effectsAbsence of melanocytesDopamine agonismSystemic medicationsTopical medicationsDopamine agonistsLegs syndromeCase reportHistopathologic examinationDermal-epidermal junctionAnterior shoulderPharmacologic substancesSide effectsPatch applicationPotential mechanismsLeukodermaMedicationsPatientsSyndromeAgonists
2021
The role of ferroptosis in melanoma
Talty R, Bosenberg M. The role of ferroptosis in melanoma. Pigment Cell & Melanoma Research 2021, 35: 18-25. PMID: 34407291, DOI: 10.1111/pcmr.13009.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune checkpoint inhibitorsNovel therapeutic targetIron-dependent regulated cell deathContext of melanomaRole of ferroptosisDysregulation of ferroptosisForms of cancerCheckpoint inhibitorsAdvanced melanomaImmunotherapy regimensMelanoma patientsTargeted therapyTherapeutic targetSkin cancerMelanomaDeadliest formTherapyRegulated cell deathFerroptosisPatientsCancerCell deathCurrent literatureRegimensRelapseTreatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis
Talty R, Damsky W, King B. Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis. JAAD Case Reports 2021, 16: 62-64. PMID: 34522749, PMCID: PMC8427262, DOI: 10.1016/j.jdcr.2021.08.012.Peer-Reviewed Original ResearchCitationsAltmetricModification and application of the proximal humerus ossification system to adolescent idiopathic scoliosis patients
Li DT, Li E, Cui JJ, Kahan JB, Petit L, Adeclat GJ, Modrak M, Talty R, Greene JD, Munger AM, Nicholson AD, Cravez E, Cooperman DR, Smith BG. Modification and application of the proximal humerus ossification system to adolescent idiopathic scoliosis patients. Spine Deformity 2021, 9: 1341-1348. PMID: 33939168, DOI: 10.1007/s43390-021-00338-y.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdolescent idiopathic scoliosisMedial physisCobb angleSurgical rangeLateral physisStage 3aIdiopathic scoliosisPercentage of patientsIdiopathic scoliosis patientsInter-observer ICCStage 3bInitial presentationPhyseal closureScoliosis patientsHigh riskPatientsSkeletal maturityPhysisHeight velocityRadiographsPeak height velocityProgressionSurgeryHigh rateScoliosis
Academic Achievements & Community Involvement
honor La Roche-Posay Medical Student Grant Targeting Melanoma and Skin Cancer
National AwardAmerican Skin AssociationDetails06/05/2023United Stateshonor Distinguished Medical Student Award
National AwardCollege of American PathologistsDetails05/01/2023United Stateshonor Society of '67 Kinney Scholars Award
National AwardAssociation of Pathology ChairsDetails04/03/2023United Stateshonor Research Excellence Award in Translational Research
Yale School of Medicine AwardYale Cancer CenterDetails07/15/2022United Stateshonor National Research Service Award F30 Fellowship
National AwardNational Cancer InstituteDetails04/05/2021United States